You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The company, which went public in June, has had to deal with issues with the US DOJ, and some private insurers. Its CEO's tenure at Sequenom was also marred by a scandal.
During the second quarter, the company performed 75,017 tests for noninvasive prenatal testing, carrier screening, and SARS-CoV-2.
The coverage comes after the women's health diagnostics firm went public last month, seeking up to $100 million in the offering.
Along with predicting preeclampsia, the Delfia Xpress sFlt-1 kit can be used to help diagnose the condition in the second and third trimesters of pregnancy.
The urine-based test, which was already available in several markets, does not require any specialized instrumentation and produces results in less than three minutes.
The companies plan to explore opportunities to use Thermo Fisher's LC-MS instrumentation to develop tools to determine the risk for adverse pregnancy outcomes.
The guidelines, drafted with support from PerkinElmer, calls for universal screening of pregnant women for preterm preeclampsia during the first trimester.
The new assay is part of the company's prenatal and women's health offerings, but it is also developing a preeclampsia test and technology for gastrointestinal testing.
An assay based on a simple dye-protein interaction is now in clinical trials, with recent research suggesting it can accurately detect preeclampsia.
NX Prenatal and Indiana University School of Medicine are collaborating to develop exosome blood tests for preterm birth risk and preeclampsia.